DRonabinol Behandling af OSA (DROSA)
Målrettet behandling af obstruktiv søvnapnø med dronabinol: Proof of Concept og fase II klinisk forsøg
This is an open-label trial that tests the effectiveness of Dronabinol in treating obstructive sleep apnea (OSA). All participants will take oral Dronabinol for two weeks. Sleep studies will be conducted before and after treatment to measure OSA severity.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Obstructive sleep apnea (OSA), is a serious respiratory disorder that involves repetitive cessation of breathing during sleep. It is estimated that 15-20 million people in the United States suffer from OSAS, which has been linked to increased risk for hypertension, heart failure, depression, and diabetes. The current standard of care for OSA, positive airway pressure (PAP), involves a mechanical device with low patient tolerance and adherence. Upper airway surgical approaches are also an option but are invasive and often unsuccessful. Effective drug treatments for OSA remain to be identified.
This study will enroll up to 120 Veterans so that 45 Veterans may complete the two-week open-label Dronabinol treatment trials. The results of the study will be used to develop a prediction model for OSA severity reduction after 2-week Dronabinol treatment vs. pretreatment AHI. Participants clinical (age, sex, body mass index, comorbidity) and pretreatment polysomnographic characteristics (sleep architecture, respiratory disturbance, and endotypes; loop-gain, arousal threshold, upper airway collapsibility and compensation) will be used to develop a prediction model for improvement of OSA with Dronabinol treatment. This prediction model will be used for a randomized clinical trial after the completion of this trial.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Karen M Lenehan
- Telefonnummer: (312) 569-6343
- E-mail: Karen.Lenehan@va.gov
Undersøgelse Kontakt Backup
- Navn: Bharati Prasad, MD
- Telefonnummer: (312) 996-8433
- E-mail: bharati.prasad@va.gov
Studiesteder
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60612
- Rekruttering
- Jesse Brown VA Medical Center, Chicago, IL
-
Kontakt:
- Howard S Gordon, MD BS
- Telefonnummer: (312) 569-7331
- E-mail: howard.gordon2@va.gov
-
Kontakt:
- Karen M Lenehan
- Telefonnummer: (312) 569-6343
- E-mail: Karen.Lenehan@va.gov
-
Ledende efterforsker:
- Bharati Prasad, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
1. AHI 15-50 per hour on pre-treatment polysomnography
Exclusion Criteria:
-
Positive Airway Pressure (PAP) treatment of obstructive sleep apnea (OSA): use > 4 hours per day for 30% of days within 3 months of enrollment. PAP use will be determined from device download data
-
Hypoglossal nerve stimulator (HNS) or oral appliance device treatment with use > 4 hours per day for 30% of days within 3 months of enrollment. HNS use will be determined by device download and oral appliance use by self-report
-
History of upper airway surgery for OSA (except adenotonsillectomy)
-
Central or mixed apneas >25% of respiratory events on diagnostic polysomnography
-
Arterial oxygen saturation < 75% for > 5% sleep time on pretreatment polysomnography
-
Body mass index > 45 kilograms per square meter (kg/m2)
-
If post-bariatric surgery, weight must be stable ±5% (per electronic medical records) for at least 6 months before the first dose of the study drug
-
Active enrollment in a weight loss program
-
Shiftwork within 3 months of enrollment
-
High-risk occupation: commercial driver and pilot
-
Motor vehicle accident or near-miss incident within 1 year of enrollment
-
Current drug or habitual alcohol use or positive urine drug screen
-
Comorbid medical and psychiatric disorders:
- Primary sleep disorders: e.g., narcolepsy, restless legs syndrome
- Uncontrolled mood disorder or a diagnosis of schizophrenia
- Initiation of new antidepressant or antipsychotic medication within 3 months
- Identified as high-risk for suicide in electronic health records
- Uncontrolled medical disorders (coronary heart disease, arrhythmia, congestive heart failure, chronic obstructive pulmonary disease, chronic hypoxemic or hypercapnic respiratory failure, stroke within 6 months of enrollment, chronic liver or kidney disease, autoimmune disorders)
-
Use of sedative-hypnotic medications within 30 days of enrollment
-
Complete blood count or liver function test values more than 1.5 times the upper limit of normal
-
Pregnancy
-
Allergy to cannabinoids or sesame oil
-
Average weekly alcohol consumption of more than 10 servings
-
Participation in other investigational protocols within 30 days of enrollment
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Single group
Open label Dronabinol treatment for two weeks. |
Open label Dronabinol treatment for two weeks.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Apnea Hypopnea Index (AHI)
Tidsramme: 2 weeks
|
The change in AHI after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms. |
2 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
T<90
Tidsramme: 2 weeks
|
The change in time below 90% oxygen saturation (T<90) after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms. |
2 weeks
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Psychomotor Vigilance Test (PVT)
Tidsramme: 2 weeks
|
The change in Lapses on Psychomotor Vigilance Test (PVT) after two weeks of Dronabinol treatment will be determined from before and after treatment PVT using a 10 minute protocol. |
2 weeks
|
|
24-hour Mean Arterial Blood Pressure (BP)
Tidsramme: 2 weeks
|
The change in 24- hour mean arterial blood pressure after two weeks of Dronabinol treatment will be determined from before and after treatment 24-hiur ambulatory BP recording. |
2 weeks
|
|
Sleep Efficiency
Tidsramme: 2 weeks
|
The change in sleep efficiency after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms. |
2 weeks
|
|
Rapid Eye Movement (REM) Sleep
Tidsramme: 2 weeks
|
The change in REM sleep after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms. |
2 weeks
|
|
Slow Wave Sleep
Tidsramme: 2 weeks
|
The change in slow wave sleep after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms. |
2 weeks
|
|
Treatment Satisfaction Questionnaire for Medication (TSQM)
Tidsramme: 2 weeks
|
Patient reported treatment satisfaction. TSQM scores have a range of 0 to 100, with higher scores indicating higher satisfaction. |
2 weeks
|
|
Epworth Sleepiness Scale (ESS)
Tidsramme: 2 weeks
|
The change in Epworth Sleepiness Scale (ESS) will be measured after two weeks of Dronabinol treatment. ESS scores have a range of 0 to 24, with higher scores indicating greater sleepiness. |
2 weeks
|
|
Functional Outcomes of Sleep Questionnaire (FOSQ)
Tidsramme: 2 weeks
|
The change in Functional Outcomes of Sleep Questionnaire (FOSQ) will be measured after two weeks of Dronabinol treatment. FOSQ score ranges from 5-20, with higher scores indicating better functional status. |
2 weeks
|
|
Pittsburgh Sleep Quality Index (PSQI)
Tidsramme: 2 weeks
|
The change in Pittsburgh Sleep Quality Index (PSQI) will be measured after two weeks of Dronabinol treatment. The PSQI score ranges from 0 to 21. Higher scores indicate poorer sleep quality. |
2 weeks
|
|
Insomnia Severity Index (ISI)
Tidsramme: 2 weeks
|
The change in Insomnia Severity Index (ISI) will be measured after two weeks of Dronabinol treatment. ISI ranges from 0 to 28, with higher scores indicating greater sleep disturbance. |
2 weeks
|
|
Post-Traumatic Stress Disorder; PTSD checklist (PCL-5)
Tidsramme: 2 weeks
|
The change in Post-Traumatic Stress Disorder; PTSD checklist (PCL-5) will be measured after two weeks of Dronabinol treatment. PCL-5 scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity. |
2 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Bharati Prasad, MD, Jesse Brown VA Medical Center, Chicago, IL
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- PULM-011-23F
- 5I01CX002632-02 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .